buyModerate
Jeffrey Stein bought $339k of CDTX
President & CEO at Cidara Therapeutics, Inc.. 4,262 shares at an average of $79.55, traded Mar 31, 2017, filed Jan 7, 2026.
Conviction score
43Value
$339k
4,262 shares
Holdings after
69,371
+7% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +15Trade size$339k at market
- +3Relative to holdingsHoldings up 7%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001478831-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 23, 2016 | JOther Common Stock | -270 | - | - | 10,025 | Jan 7, 2026 |
| Mar 31, 2017 | JOther Common Stock | -645 | $155.00 | $100k | 9,380 | Jan 7, 2026 |
| Mar 31, 2017 | POpen-market purchase Common Stockindirect: By trust | +645 | $155.00 | $100k | 65,754 | Jan 7, 2026 |
| Jun 5, 2017 | JOther Common Stock | -750 | $118.95 | $89k | 8,630 | Jan 7, 2026 |
| Jun 5, 2017 | POpen-market purchase Common Stockindirect: By trust | +750 | $118.95 | $89k | 66,504 | Jan 7, 2026 |
| Sep 12, 2017 | JOther Common Stock | -367 | $135.80 | $50k | 8,263 | Jan 7, 2026 |
| Sep 12, 2017 | POpen-market purchase Common Stockindirect: By trust | +367 | $135.80 | $50k | 66,871 | Jan 7, 2026 |
| Nov 10, 2020 | JOther Common Stock | -2,500 | $40.01 | $100k | 5,763 | Jan 7, 2026 |
| Nov 10, 2020 | POpen-market purchase Common Stockindirect: By trust | +2,500 | $40.01 | $100k | 69,371 | Jan 7, 2026 |
| Dec 10, 2020 | JOther Common Stockindirect: By son | -658 | $0.00 | $0 | 1,442 | Jan 7, 2026 |
| Dec 31, 2021 | GGift Common Stockindirect: By trust | -1,873 | $0.00 | $0 | 67,498 | Jan 7, 2026 |
| Dec 31, 2021 | GGift Common Stockindirect: By son | +937 | $0.00 | $0 | 2,379 | Jan 7, 2026 |
Related signals
Other insiders at Cidara Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | CDTXsell Cidara Therapeutics, Inc. | Shane Ward COO & CLO | $2.2M 9,959 shares | -28% | |
| 20Weak | CDTXsell Cidara Therapeutics, Inc. | Nicole Negar Davarpanah Chief Medical Officer | $30k 474 shares | -1% | |
| 50Moderate | CDTXbuy Cidara Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $100M 2,272,727 shares | +208% | |
| 31Weak | CDTXbuy Cidara Therapeutics, Inc. | Chrysa Mineo director | $74k 3,320 shares | - | |
| 29Weak | Cidara Therapeutics, Inc. | Leslie Tari CHIEF SCIENTIFIC OFFICER | $39k 1,773 shares | -10% | |
| 39Weak | Cidara Therapeutics, Inc. | Shane Ward COO & CLO | $37k 1,664 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.